Figure 4From: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersPrognostic values of the four biomarker groups in the second cohort of tamoxifen-treated patients. Kaplan-Meier estimates of 10-year distant event-free survival (DEFS) of the four biomarker groups obtained by combining low and high mitosis kinase score (MKS) and estrogen-related score (ERS) in all patients (A) and node-negative patients (B). Annual hazard rates for distant recurrences by biomarker-group estimates using kernel-based methods for all patients (C). Landmark analyses of the Kaplan-Meier estimates of DEFS during the first 5 years (left side of the panel) and from 5 to 10 years (right side of the panel) is shown for the high-MKS groups by ERS (high and low) (D). loP, low MKS; hiP, high MKS; loER, low ERS; hiER, high ERS).Back to article page